Anil Panackal

Merck & Co. Inc., USA


Anil Panackal received his M.D. degree from Yale in 1997. After completing internal medicine residency at University of California, he served as an Officer in the US Epidemic Intelligence Service (EIS) at CDC. At that time, his team field investigations included (1) the Rift Valley fever outbreak in Saudi Arabia and Yemen, its first occurrence outside the African continent; (2) identification of a new endemic focus of coccidioidomycosis; (3) an outbreak of invasive aspergillosis among renal transplant recipients; (4) a large outbreak of histoplasmosis among college spring breakers; (5) emergency room syndromic surveillance following the World Trade Center attack; and (6) the inhalational anthrax investigation in Florida, discovering a clue that the mail was the putative source as a member of the team. He completed his infectious diseases fellowship at University of Washington, before going on to teach and practice, while obtaining his M.S. degree in epidemiology, at Harvard, University, Cambridge, MA, USA. He then became Chief of Infectious Diseases/Tropical Medicine at the US Department of State, continuing to serve as an educator at Uniformed Services University of the Health Sciences (USUHS) before pursuing a more academic track as Staff Clinician in the Translational Mycology Unit at NIH/NIAID, focusing on cryptococcosis in previously healthy adults. He is now a Director at Merck & Co. Inc., in the field of antimicrobial resistance. He is a Fellow of the American College of Physicians (FACP) and Infectious Diseases Society of America (FIDSA) and is Board Certified in Infectious Diseases via the American Board of Internal Medicine and in Tropical Medicine via the American Society of Tropical Medicine and Hygiene.

Biography Updated on 14 March 2017

Scholarly Contributions [Data Provided by ]